NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Gene Therapy Weekly



Gene Therapy Weekly is the most comprehensive publication covering gene research for disease treatment and drug development.

Not only does Gene Therapy Weekly bring you more reports, but more coverage of every aspect of gene therapy research, from drug candidate identification through launch and beyond.

Published weekly, each issue of Gene Therapy Weekly has an average of more than 85 articles that cover gene therapy research from A-Z, including antisense technology, cancer gene therapies, recombinant antibodies, associated genomics studies, vector development and other gene delivery systems, as well as pertinent genetic, proteomic and cell biology studies.

But important gene therapy research news is only half the picture. Gene Therapy Weekly also provides key business intelligence regarding marketing, distribution, licensing, regulatory actions, personnel and funding for the pharmaceutical and biotech companies involved in gene therapy research and drug manufacturing.

Comprehensive Gene Therapy Research Coverage



NewsRx editors collect coverage from more than 4,000 peer-reviewed journals, dozens of industry meetings, medical news wires, pharmaceutical and biotech company internet sites, purchased databases, and press releases.

Each article, usually no more than 500 words, is written to be an information-heavy, concise report of the important facts, together with full references and citations for original source material. You get a fast, user-friendly read that keeps you on top of all the important gene therapy research-related developments for that week.

Latest Gene Therapy Research and Genetic Disease News Delivered to Your Desktop



Gene Therapy Weekly is available in print or online at www.NewsRx.com. Email versions can be delivered directly to your desktop. Site licenses are also available for corporate use.

Combination print and email subscriptions are available, and all subscriptions come with online access to Gene Therapy Weekly's archives, which go back to 1995. See a sample issue here

Best Weekly Gene Therapy Research News



Gene Therapy Weekly was the first and only newsletters dedicated solely to gene therapy reporting. We stake our 20-plus year history as a healthcare publisher that it remains the best.

But don't take our word for it. Sign up for our six-week, no-risk free trial and see for yourself. Receive six issues of Gene Therapy Weekly, more than 500 articles, and see why it will become your indispensable tool for tracking gene therapy research news and developments.

Subscribe Now and Receive Instant $300 Online Savings



Subscribe now and we'll give you $300 off our regular subscription price. You get the power of the most comprehensive gene therapy research coverage in the industry at a great discount.

Start today, and eliminate all those hours you normally spend scanning dozens of periodicals, websites, and other information sources. We've done it for you; Gene Therapy Weekly has got you covered.

Title:Gene Therapy Weekly
Frequency:52
Print ISSN Number:1078-2842
Online ISSN Number:1532-4583


Worldwide - One Year Single User Online Access & E-mail Delivery $2595.00 $2295.00
US & Canada - One Year Print Publication Subscription $2595.00 $2295.00
US & Canada - One Year Print & Online Publication Subscription $2825.00 $2525.00
All Other Countries - One Year Print Publication Subscription $2795.00 $2495.00
All Other Countries - One Year Print & Online Publication Subscription $3055.00 $2755.00
One Year Site License for One Geographic Location: $5,190.00 Please Call


Newsletter Archive

Browse Our Issue Archives for Gene Therapy Weekly



See the table of contents and sample articles for any issue by clicking a date below.

------


NewsRx Passes
Advertisement
Top 10

------------------------
Security by Verisign PR Login